Daniel R Deaver
Overview
Explore the profile of Daniel R Deaver including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cunningham J, Todtenkopf M, Dean R, Azar M, Koob G, Deaver D, et al.
Pharmacol Biochem Behav
. 2021 Mar;
204:173157.
PMID: 33647274
Opioid receptors modulate neurochemical and behavioral responses to drugs of abuse in nonclinical models. Samidorphan (SAM) is a new molecular entity that binds with high affinity to human mu- (μ),...
2.
Burke N, Li Y, Deaver D, Finn D, Roche M, Eyerman D, et al.
J Psychopharmacol
. 2019 Sep;
33(12):1620-1627.
PMID: 31512988
Background: The combination of buprenorphine, a partial mu-opioid receptor agonist and a functional kappa-opioid receptor antagonist, with samidorphan, a functional mu-opioid receptor antagonist, is being developed as an adjunct therapy...
3.
Cunningham J, Eyerman D, Todtenkopf M, Dean R, Deaver D, Sanchez C, et al.
J Psychopharmacol
. 2019 Jul;
33(10):1303-1316.
PMID: 31294646
Background: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831,...
4.
Burke N, Ferdousi M, Deaver D, Finn D, Roche M, Kelly J
Neuropharmacology
. 2018 Dec;
146:327-336.
PMID: 30553825
Modulation of the opioid system has re-emerged as a potential therapeutic avenue for treating depression, with efficacy of a fixed-dose combination of buprenorphine (BUP), a partial μ-opioid receptor (MOR) agonist...
5.
Smith K, Cunningham J, Eyerman D, Dean 3rd R, Deaver D, Sanchez C
Neuropharmacology
. 2018 Nov;
146:316-326.
PMID: 30448421
Approximately two-thirds of major depressive disorder (MDD) patients do not respond adequately to current therapies. BUP/SAM (ALKS 5461), a combination of buprenorphine (BUP) and samidorphan (SAM), is a novel opioid...
6.
Sgro M, Modlin D, Deaver D, Kallman M, Todtenkopf M
Drug Dev Res
. 2018 Sep;
79(5):234-238.
PMID: 30188587
Methods: Escalating doses of samidorphan were substituted for morphine and rats were allowed to respond on two levers for food reward. Doses of samidorphan were chosen based on other pharmacodynamic...
7.
Bidlack J, Knapp B, Deaver D, Plotnikava M, Arnelle D, Wonsey A, et al.
J Pharmacol Exp Ther
. 2018 Aug;
367(2):267-281.
PMID: 30108159
A combination of buprenorphine (BUP) and samidorphan (SAM) at a 1:1 (mg/mg) fixed-ratio dose is being investigated as an adjunctive treatment of major depressive disorder (BUP/SAM, ALKS 5461). Both [H]BUP...
8.
Callaghan C, Rouine J, Dean R, Knapp B, Bidlack J, Deaver D, et al.
Brain Behav Immun
. 2017 Aug;
67:152-162.
PMID: 28844812
Patients receiving the cytokine immunotherapy, interferon-alpha (IFN-α) frequently present with neuropsychiatric consequences and cognitive impairments. Patients (25-80%) report symptoms of depression, including, anhedonia, irritability, fatigue and impaired motivation. Our lab...
9.
Burke N, Coppinger J, Deaver D, Roche M, Finn D, Kelly J
Physiol Behav
. 2016 Sep;
167:28-34.
PMID: 27591842
Depression is a debilitating psychiatric disorder that is highly comorbid with anxiety. Depression is twice as prevalent in women as in men, however, females remain underrepresented in preclinical research. The...
10.
Paquette S, Dawit H, Hickey M, Merisko-Liversidge E, Almarsson O, Deaver D
Pharm Res
. 2014 Feb;
31(8):2065-77.
PMID: 24558010
Purpose: Long-acting injectables (LAIs) are increasingly recognized as an effective therapeutic approach for treating chronic conditions. Many LAIs are formulated to create a poorly soluble depot from which the active...